AxoGen Analyst & Investor Day Nov 2017

New York, November 20, 2017


Please join AxoGen executives and physician thought leaders for a discussion of new clinical developments in peripheral nerve repair and the company’s growing platform for nerve repair.  

Expert Speakers:

Dr. Kyle Eberlin - Massachusetts General Hospital, Boston, MA
Dr. Constance Chen - Lenox Hill Hospital, New York City, NY
Dr. John Zuniga – UT Southwestern Medical Center, Dallas, TX
Dr. Ivica Ducic - AxoGen Medical Director & Washington Nerve Institute, McLean, VA

Revenue generating, dedicated to peripheral nerve repair with a portfolio of regenerative medicine products available in the US, Canada and several other countries. Products include Avance Nerve Graft, off-the-shelf commercially available processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site. 2Q17 Revenue of $15.2M, up 46% compared to $10.4M in 2Q16.

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

AxoGen [AXGN] US$804 MM MCap
Rev gen­er­at­ing; ad­dress­ing pe­ripher­al nerve re­pair w port­fo­lio of re­gen­er­a­tive medicine prod­ucts in US, Ca­na­da et al. Prod­ucts in­cl. Avance Nerve Graft: off-the-shelf com­mer­cial­ly avail pro­cessed... [more in­for­ma­tion]